Dermatologic adverse events related to the PI3Kα inhibitor alpelisib (BYL719) in patients with breast cancer
Diana G. Wang, Dulce M. Barrios, Victoria Blinder, Jacqueline Bromberg, Pamela Drullinsky, Samuel A. Funt, Komal Jhaveri, Diana Lake, Tomás G. Lyons, Shanu Modi, Pedram Razavi, Michelle Sidel, Tiffany A. Traina, Linda T. Vahdat, Mario E. Lacouture
Topics & Concepts
MedicineRashMaculopapular rashAdverse effectBreast cancerDermatologyCancerInternal medicineRetrospective cohort studySurgeryPI3K/AKT/mTOR signaling in cancerAdvanced Breast Cancer TherapiesChronic Myeloid Leukemia Treatments